Bio-Techne Co. (NASDAQ:TECH) Shares Bought by Simon Quick Advisors LLC

Simon Quick Advisors LLC lifted its holdings in shares of Bio-Techne Co. (NASDAQ:TECH) by 11.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,560 shares of the biotechnology company’s stock after acquiring an additional 485 shares during the quarter. Simon Quick Advisors LLC’s holdings in Bio-Techne were worth $328,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. UMB Bank n.a. increased its holdings in Bio-Techne by 46.4% during the 4th quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 168 shares during the last quarter. Brooklyn Investment Group acquired a new stake in shares of Bio-Techne during the third quarter worth approximately $39,000. Quest Partners LLC bought a new stake in shares of Bio-Techne in the third quarter worth $43,000. MassMutual Private Wealth & Trust FSB raised its holdings in Bio-Techne by 60.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 672 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 253 shares in the last quarter. Finally, Mather Group LLC. raised its holdings in Bio-Techne by 51.5% in the third quarter. Mather Group LLC. now owns 612 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 208 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Bio-Techne Stock Performance

Shares of TECH stock opened at $76.91 on Friday. The company has a market cap of $12.22 billion, a P/E ratio of 81.82, a PEG ratio of 5.81 and a beta of 1.27. The business has a 50 day moving average of $73.94 and a two-hundred day moving average of $74.46. Bio-Techne Co. has a 52 week low of $61.16 and a 52 week high of $85.57. The company has a quick ratio of 3.26, a current ratio of 4.56 and a debt-to-equity ratio of 0.14.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.04. Bio-Techne had a return on equity of 12.76% and a net margin of 12.86%. The business had revenue of $289.46 million during the quarter, compared to analyst estimates of $280.22 million. During the same quarter in the previous year, the firm posted $0.35 EPS. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, analysts anticipate that Bio-Techne Co. will post 1.68 EPS for the current year.

Bio-Techne Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 22nd. Investors of record on Monday, November 11th were issued a $0.08 dividend. The ex-dividend date was Friday, November 8th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.42%. Bio-Techne’s dividend payout ratio (DPR) is presently 34.04%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TECH. Scotiabank boosted their target price on shares of Bio-Techne from $83.00 to $88.00 and gave the stock a “sector outperform” rating in a research report on Thursday, October 31st. StockNews.com upgraded Bio-Techne from a “hold” rating to a “buy” rating in a research note on Tuesday, November 12th. Finally, Robert W. Baird upped their price objective on Bio-Techne from $82.00 to $84.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $82.00.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.